Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pulsenmore Ltd (PLSM) Fair Value & Analysis

Healthcare · US · Market cap $22.4M

Price$3.41
Fair Value$11.55
Upside+238.7%
Quality95/100
Evidence: Low Range $7.62 – $14.44

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pulsenmore Ltd (PLSM) currently trades at $3.41, while our model-based Fair Value estimate is $11.55 — implying the stock looks roughly 238.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Pulsenmore Ltd (PLSM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $11.55 versus a price of $3.41 — about +239% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PLSM?
Our 21-model fair value for Pulsenmore Ltd is $11.55 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.41.
What is the quality score of PLSM?
Pulsenmore Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.